HEXVIX

This brand name is authorized in Austria, Estonia, Finland, France, Ireland, Lithuania, New Zealand, Poland, Spain, UK.

Active ingredients

The drug HEXVIX contains one active pharmaceutical ingredient (API):

1	Hexaminolevulinate UNII D4F329SL1O - HEXAMINOLEVULINATE HYDROCHLORIDE
	Hexaminolevulinate blue light fluorescence cystoscopy is indicated as adjunct to standard white light cystoscopy to contribute to the diagnosis and management of bladder cancer in patients with known or high suspicion of bladder cancer.
	Read more about Hexaminolevulinate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HEXVIX Powder and solvent for intravesical solution	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V04CX	Other diagnostic agents	V Various → V04 Diagnostic agents → V04C Other diagnostic agents
Discover more medicines within V04CX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1165902
ES	Centro de información online de medicamentos de la AEMPS	66925
FI	Lääkealan turvallisuus- ja kehittämiskeskus	373205
FR	Base de données publique des médicaments	61196720
GB	Medicines & Healthcare Products Regulatory Agency	113900
LT	Valstybinė vaistų kontrolės tarnyba	1080949
NZ	Medicines and Medical Devices Safety Authority	18731
PL	Rejestru Produktów Leczniczych	100147527